ImClone (NASDAQ: IMCL) implied volatility elevated prior to positive Erbitux data.
- IMCL, an oncology care company, is recently trading up $11.05 to $48.98 in pre-open trading.
- Merck KGaA & IMCL announced that Erbitux met the primary endpoint outcomes from the FLEX trial (a phase 3 study of 1000 patients with previously untreated non-small cell lung cancer).
- Goldman Sachs says, "Erbitux data in lung cancer positive for IMCL, Minor neg for DNA."
- IMCL October option implied volatility of 46 is above its 26-week average of 40 according to Track Data, suggesting larger price risks.
Genentech (NYSE: DNA) September volatility at 21 prior to IMCL's NCSCLC data.
- DNA is recently trading at $76 in pre-open trading, below its close of $79.15.
- Merck KGaA & IMCL announced that Erbitux met the primary endpoint outcomes from the FLEX trial (a phase 3 study of 1000 patients with previously untreated non-small cell lung cancer (NSCLC).
- DNA September option implied volatility is at 21; October is at 25. DNA's average option implied volatility over the last 26-weeks is 24 according to Track Data, suggesting non-directional near term price fluctuations.
Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.
Will Rich Ross really have a positive impact on Disney's movie operations?
Consumers sick of recession, may spend extra on holidays
Corrections, seasonality and Santa Claus
